Etna, NH, United States of America

Ta-Yuan Chang

This inventor holds 16 USPTO granted patents and 1 published patent application, primarily in Cholesterol Metabolism. Top assignees: Dartmouth College, Other. Active years: 1996-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ta-Yuan Chang. Retrieved from https://idiyas.com/inventor/ta-yuan-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 68.8

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 42(Granted Patents)


Location History:

  • Hanover, NH (US) (1996 - 2008)
  • Etna, NH (US) (2003 - 2018)

Company Filing History:


Years Active: 1996-2018

Loading Chart...
Areas of Expertise:
ACAT1 Inhibition
Neurodegenerative Diseases
Obesity Treatment
Cholesterol Detection
Niemann-Pick Disease
High-Throughput Screening
SREBP Pathway
Cholesterol Acyltransferase
Allosteric Inhibitors
Metabolic Syndrome
16 patents (USPTO):Explore Patents

Title: Ta-Yuan Chang: Innovator in Neurodegenerative Disease Treatment

Introduction

Ta-Yuan Chang is a prominent inventor based in Etna, NH (US), known for his significant contributions to the field of medical research. With a total of 16 patents to his name, he has focused on developing innovative methods for treating various health conditions, particularly neurodegenerative diseases and metabolic disorders.

Latest Patents

Among his latest patents, Ta-Yuan Chang has developed a method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases. This invention features methods for stimulating the clearance of misfolded or aggregated proteins or peptides in microglia or neurons. It aims to treat neurodegenerative diseases associated with such pathology in the brain by selectively inhibiting the expression or activity of Acyl-CoA: Cholesterol Acyltransferase 1, while not affecting Acyl-CoA: Cholesterol Acyltransferase 2. Another notable patent focuses on selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis. This invention presents methods for preventing and treating these related diseases by inhibiting ACAT1 activity or expression in myeloid cells.

Career Highlights

Ta-Yuan Chang has had a distinguished career, working at Dartmouth College, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding and treatment of complex health issues.

Collaborations

Throughout his career, Ta-Yuan Chang has collaborated with notable individuals, including Catherine C Y Chang and Yohei Shibuya. These collaborations have further enriched his research and innovation efforts.

Conclusion

Ta-Yuan Chang's innovative work in the field of medical research has led to significant advancements in the treatment of neurodegenerative diseases and metabolic disorders. His contributions continue to impact the scientific community and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…